Administrative Patent Judge, USPTOBismarck Myrick, Director of the Office of Equal Employment Opportunity and Diversity, USPTOCara Duckworth, Chief Corporate Communications Officer, USPTOShirin Bidel-Niyat, Chief of Staff, USPTOAlternate: Robin Evans, Deputy Commissioner for Patents, USPTOAlternate: Amy Cotton, Deputy Commissioner for Trademark].Public Roundtable on Protections for Name, Image, Likeness, Other Indicia of Identity, and Reputation, 89 FR 54442 (July 1, 2024) [providing notice of public “roundtable to seek public input regarding: whether existing laws protecting an individual’s reputation and existing laws prohibiting unauthorized use of an individual’s name, image, voice, likeness, or other indicia of identity … are sufficient given the development and proliferation of artificial intelligence (AI) technology.”].Final RulesThere are no new final rules.Interim RulesThere are no new interim rules.Proposed RulesWithdrawal of Changes to Post Registration Response Deadlines, 89 FR 58660 (July 19, 2024) [providing notice of proposed rule to withdraw previously postponed portions of regulations implementing the Trademark Modernization Act that would have imposed a shortened three-month response period extendable by three months for post-registration actions for maintenance and renewal filings].LegislationOn July 2, Representatives Young (R-CA) and Moolenaar (R-MI) introduced a bill titled “Protecting American Innovation and Development Act of 2024” or the “PAID Act of 2024” to “require the Secretary of Commerce to identify and report on foreign adversary entities using intellectual property related to emerging technology without a license, and for other purposes.”On July 11, the Affordable Prescriptions for Patients Act of 2023 passed in the Senate. According to the bill’s summary, it provides limits on patent litigation concerning biological products, including articulating a limit on the number of patents that may be asserted in a litigation in certain instances.On July 11, Senators